Hematological Oncology

Article	Citations
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016	36
	31
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS	29
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis	29
Regulatory approvals and survival benefit for novel lymphoma drugs from 2013–2022	29
REAL‐WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA	28
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)	26
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK	26
PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)	25
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived Models	25
QUALITY OF LIFE IN PEDIATRIC HIGH‐RISK HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐BASED INTENSIVE CHEMOTHERAPY—COMPARISON TO HISTORICAL TREATMENT COHORT AND HEALTHY PEERS	24
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphoma	23
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY	21
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma	21
EFFICACY OF FRONT‐LINE IMMUNOCHEMOTHERAPY FOR TRANSPLANT‐INELIGIBLE MANTLE CELL LYMPHOMA: A NETWORK META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	21
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)	21
PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS	20
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma	20
Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders	18
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma	18
MINIMAL RESIDUAL DISEASE STATUS IMPROVED THE RESPONSE EVALUATION IN PATIENTS WITH WALDENSTRöM’S MACROGLOBULINEMIA	18
Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis	18
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial	17
	17
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	17

A comprehensive analysis of coagulopathy during anti‐B cell maturation antigen chimeric antigen receptor‐T therapy in multiple myeloma, a retrospective study based on LEGEND‐2	17
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime	17
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma	17
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma	16
490 | MOLECULAR LANDSCAPE OF DISTINCT FOLLICULAR LYMPHOMA HISTOLOGIC GRADES: INSIGHTS FROM GENOMIC AND TRANSCRIPTOME ANALYSES	15
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax	15
514 | CAN BASELINE 18F‐FDG PET/CT PREDICT THE PROGNOSIS OF PRIMARY CNS LYMPHOMA?	15
825 | MEASURING SYMPTOM IMPROVEMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: EMERGING RESULTS FROM AN INCLUSIVE, ITERATIVE PROCESS	15
522 | CLINICAL APPROACH AND OUTCOME OF DIFFUSE LARGE B CELL LYMPHOMA WITH PERSISTENT PET POSITIVITY AFTER FRONTLINE TREATMENT: SUBGROUP ANALYSIS OF THE STRIDER STUDY	15
439 | ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	15
580 | CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF HIGH‐GRADE B‐CELL LYMPHOMAS TRANSFORMED FROM INDOLENT LYMPHOMAS IN HIV‐NEGATIVE AND HIV‐POSITIVE PATIENTS	14
546 | PATIENT REPORTED OUTCOMES AND PREDICTORS OF INHIBITOR USE IN CHRONIC LYMPHOCYTIC LEUKEMIA—AN ANALYSIS OF THE LYMPHOMA COALITION’S 2024 GLOBAL PATIENT SURVEY	14
639 | DIFFUSE LARGE B CELL LYMPHOMA: A TUNISIAN MULTICENTER EXPERIENCE	13
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions	13
613 | LIMITED‐STAGE MANTLE CELL LYMPHOMA: CLINICAL FEATURES, MANAGEMENT, AND OUTCOMES IN A MULTICENTER RETROSPECTIVE STUDY FROM SPAIN	13
660 | IMPACT OF HEALTHCARE SETTING ON DIFFUSE LARGE B‐CELL LYMPHOMA OUTCOMES—A REAL‐WORLD COMPARATIVE STUDY	13
617 | INCIDENCE AND SURVIVAL OF MANTLE CELL LYMPHOMA IN ENGLAND 2014–2021: A NATIONAL COHORT STUDY FROM THE UNCOVER STUDY GROUP	13
How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia	12
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects	12
801 | AS A NOVEL EPIGENETIC MODULATOR, EZH1/2 DUAL INHIBITOR HM97662 EXHIBITS ANTITUMOR EFFICACY IN HEMATOLOGICAL MALIGNANCIES AND OVERCOMES EZH2‐INHIBITOR MEDIATED RESISTANCE	12
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma	12
Clonal Hematopoiesis: Impact on Health and Disease	12
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis	12
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model	12
161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM	12
295 | EARLY MORTALITY DLBCL PREDICTION WITH AN ENHANCED R‐IPI SCORE DEVELOPED USING AN ENSEMBLE MACHINE LEARNING MODEL	11
407 | RADIATION THERAPY FOR OLIGO‐RELAPSED/PROGRESSIVE DISEASE POST‐STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA: FACTORS ASSOCIATED WITH FAVORABLE OUTCOMES	11
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia	11
216 | EPCORITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL‐1	11
361 | REAL‐WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE	11
290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY	11
324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA	11
240 | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3‐YEAR FOLLOW‐UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	11
372 | DECODING THE CD4+T CELL‐ HODGKIN REED‐STERNBERG CELL CROSSTALK: HOW TO CUT THE ACHILLES' HEEL OF PEDIATRIC HODGKIN LYMPHOMA?	11
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study	11
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study	10
Issue Information	10
Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting	10
Promising clinical efficacy and acceptable safety profile of sequential P‐GEMOX and radiotherapy for localized ENKTL	10
Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma	10
Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)	10
Ultrasonography‐guided core‐needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front‐line biopsies in a multicenter Italian study	10
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies	10
Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti‐CD19 chimeric antigen receptor T‐cell	10
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational study	9
Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non‐H.pylori Helicobacter using multiplex PCR: a retrospective analysis	9
Treatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvement	9
CHROMATIN ACCESSIBILITY PROFILING TO INCREASE DIAGNOSTIC ACCURACY AND REFINE CELL‐OF‐ORIGIN CLASSIFICATION OF MATURE T‐CELL LYMPHOMAS	9
Deregulated hsa‐miR‐23a‐3p and hsa‐mir‐148a‐3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesis	9
IMMUNE PROFILE IN THE PERIPHERAL BLOOD (PB) OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT DIAGNOSIS AND UPON RELAPSE	9

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA	9
LYMPHOMA TISSUE EXPLANTS TO ANTICIPATE RESPONSE TO TARGETED THERAPIES	9
BRCA1/2 MUTATIONS IMPACT ON THE DEVELOPMENT OF BREAST IMPLANT‐ASSOCIATED LYMPHOMA (BIA‐ALCL) IN WOMEN WITH BREAST CANCER RECONSTRUCTED WITH TEXTURED BREAST IMPLANTS	9
Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study	9
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL	9
INVESTIGATING THE SAFETY AND EFFICACY OF IV FENTANYL FOR BROWN FAT MITIGATION IN 18FDG‐PET/CT IN PEDIATRIC ONCOLOGY: A MULTI‐INSTITUTIONAL EXPERIENCE	9
ELUCIDATING THE MOLECULAR MECHANISMS OF CLONAL EVOLUTION IN MULTIPLE MYELOMA THROUGH SINGLE‐CELL RNA SEQUENCING	9
TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA	9
A PREDICTIVE MODEL FOR ULTRA‐HIGH RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE‐CENTER STUDY IN CHINA	9
EPIGENETIC REGULATION OF IMMUNE MICROENVIRONMENT INTERACTIONS IN LYMPHOMA	9
Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience	8
Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience	8
456 | IDENTIFICATION OF AN OPTIMAL ABSOLUTE LYMPHOCYTE COUNT BEFORE LEUKAPHERESIS IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CART	8
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center	8
876 | LYMPHOMA‐ASSOCIATED BONE MARROW HEMOPHAGOCYTOSIS: A RETROSPECTIVE, SINGLE‐CENTER STUDY OF 67 PATIENTS	8
855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE	8
EFFICACY AND SAFETY OF BTK INHIBITORS IN VITREORETINAL LYMPHOMA: A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF 24 PATIENTS	8
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDY	8
192 | FOLLICULAR LYMPHOMA DISPLAYS DISTINCT GENE EXPRESSION PROFILES ACCORDING TO HISTOLOGICAL GRADE	8
57 | CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL	8
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib	8
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis	8
TUESDAY, 13 JUNE 2023 FROM 16:30 TO 18:00 CEST (ROOM B2)	8
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study	8
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL)	8
197 | CD4+ T CELL RECRUITMENT AND DIFFERENTIATION INTO A CYTOTOXIC PHENOTYPE IS ASSOCIATED WITH THE TREATMENT OF PATIENTS WITH GLOFITAMAB TOGETHER WITH R‐CHOP OR POLA‐R‐CHP	8
202 | IMMUNOSURVEILLANCE OF PRECANCEROUS GERMINAL CENTER B CELLS	8
263 | LONG‐TERM OUTCOMES IN WALDENSTRÖM MACROGLOBULINEMIA PATIENTS WHO DISCONTINUE BRUTON TYROSINE KINASE INHIBITOR THERAPY	8
40 | THE DIRECT STUDY: A ROADMAP FOR ctDNA‐BASED RISK PREDICTION, MOLECULAR PROFILING AND MRD DETECTION IN DIFFUSE LARGE B CELL LYMPHOMA	8
Remote Monitoring of CAR T‐Cell Treated Patients by a Specialized Nurse to Detect and Manage Late Complications: Report of the CARAMA Program	8
830 | A PHASE 1 STUDY EVALUATING SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV‐291, A CD79B‐TARGETING ADC IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA	8
863 | RADIOTHERAPY IN PREGNANT PATIENTS WITH HODGKIN’S LYMPHOMA: CLINICAL OUTCOMES AND DOSIMETRIC ASSESSMENT	8
MR‐GUIDED ADAPTIVE RADIOTHERAPY FOR GASTRIC LYMPHOMA, PRELIMINARY RESULTS FROM ONGOING STUDY	8
79 | OUTCOME OF AUTOLOGOUS AND ALLOGENIC HCT IN BURKITT LYMPHOMA: AN EBMT REGISTRY ANALYSIS	8
363 | REAL‐WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: 2‐YEAR FOLLOW‐UP FROM THE GATLA STUDY	7
515 | PREDICTIVE VALUE OF INTERIM AND END OF TREATMENT PET/CT IN FRONT‐LINE TREATMENT OF PERIPHERAL T‐CELL LYMPHOMA	7
Issue Information	7
HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY	7
Post‐transplant lymphoproliferative disease in children, adolescents, and young adults	7
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study	7
510 | THE ANTIBODY‐DEPENDENT CELLULAR CYTOTOXICITY AND METABOLIC TUMOR VOLUME BALANCE: A NOVEL PREDICTIVE MARKER FOR TUMOR RECURRENCE IN DIFFUSE LARGE B‐CELL LYMPHOMA	7
538 | IGVH MUTATIONAL STATUS AS A PROGNOSTIC FACTOR AFFECTING RELAPSE‐FREE SURVIVAL AND TREATMENT‐FREE INTERVAL IN CLL PATIENTS: SINGLE‐CENTER EXPERIENCE WITH 110 CASES	7
802 | A STUDY ON THE MECHANISM OF THE NOVEL HIGHLY SELECTIVE HDAC INHIBITOR PURINOSTAT MESYLATE IN DOUBLE‐HIT LYMPHOMA AND ITS THERAPEUTIC POTENTIAL COMBINATION WITH VENETOCLAX	7
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma	7
Distinguishing myelodysplastic syndromes with moderate‐to‐severe bone marrow fibrosis from triple‐negative primary myelofibrosis based on clinical and genetic covariates	7
COMBINING BASELINE TOTAL METABOLIC TUMOR VOLUME AND BETA‐2‐MICROGLOBULIN LEVELS PREDICTS OUTCOMES IN HIGH BURDEN FOLLICULAR LYMPHOMA	7
FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia	7
512 | PROGNOSTIC VALUE OF BASELINE METABOLIC BIOMARKERS ASSESSED BY F18‐FDG PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA	7
672 | REAL‐WORLD DATA OF LISOCABTAGENE MARALEUCEL AS SECOND LINE THERAPY FOR PATIENTS WITH LARGE B‐CELL LYMPHOMA: FIRST RESULTS OF THE FRENCH DESCAR‐T REGISTRY BY LYSA	7
758 | CLINICAL OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEPATOSPLENIC T‐CELL LYMPHOMA	7
A REAL‐WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA IN CHINA	7
COVID‐19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation	7
The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas	6
PHASE‐2 FIRST‐IN‐INDIA INDUSTRY STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN‐003A) IN RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY B‐NHL SUBANALYSIS	6
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0	6
Issue Information	6
Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerability	6
THE ROLE OF CD5+ AS AGGRESSIVE BIOMARKER IN DIFFUSE LARGE B‐CELL LYMPHOMA	6
DARATUMUMAB AND EPOCH FOR HIV+/‐ PLASMABLASTIC LYMPHOMA: A FEASIBILITY STUDY OF THE AIDS MALIGNANCY CONSORTIUM (AMC 105)	6
RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI)	6
TAyloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B‐cell NHL	6
REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL	6
Phase 2 study to investigate the efficacy and safety of IMC‐001, anti‐PD‐L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study	6
ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R‐CHOP‐LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON‐GCB DLBCL	6
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.	6
Predicting ICANS by means of plasma CAR‐T cell derived extracellular vesicles in patients undergoing infusion of anti‐CD19 CAR‐T cells	6
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents	6
PERIPHERAL T CELL LYMPHOMA (PTCL) AND TREATMENT OUT‐COME SINGLE CENTRE RETROSPECTIVE STUDY	6
Combined single‐cell and spatially‐resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organization	6
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis	6
KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA	6
Metabolic reprograming of exhausted intratumoral CD8+ T‐cell underlies anti‐tumor activity of SUMOylation inhibitors in Large B Cell Lymphoma	6
Genomic abnormalities involving class I HLA are common in advanced cutaneous T‐cell lymphoma	6
PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS	6
A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD courses	6
POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA	6
169 | PHOSPHO‐STAT3 EXPRESSION AND JAK/STAT PATHWAY ACTIVATION ACROSS GENETIC SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA	5
619 | IMPACT OF ASCT CONSOLIDATION AND RITUXIMAB MAINTENANCE ON SURVIVAL IN REAL‐WORLD PATIENTS WITH MANTLE CELL LYMPHOMA IN SPAIN. THE GELTAMO‐MCL‐2022 STUDY	5
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy	5
508 | BAYESIAN PENALIZED LIKELIHOOD RECONSTRUCTION ALGORITHM RESULTS IN SIMILAR PROGNOSTIC MARKERS ON FDG PET/CT IN DLBCL	5

537 | CLINICAL CHARACTERISTICS OF HEPATITIS B VIRUS REACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB: A RETROSPECTIVE MULTICENTRIC STUDY	5
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL	5
Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patients	5
873 | DISPARITIES IN LYMPHOMA TREATMENT ACCESS AT RIAU, ONE OF PROVINCE IN INDONESIA: WHEN LATE DIAGNOSIS AND UNEQUAL CARE DEFINE OUTCOMES	5
768 | EFFICACY AND SAFETY OF SELINEXOR‐MELPHALAN COMBINED CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA	5
859 | NOVEL APPLICATION OF DEEP‐LEARNING BASED MRI FOR DETECTION, SEGMENTATION, AND RADIOTHERAPY RESPONSE ASSESSMENT IN PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA	5
742 | OUTCOME OF PATIENTS WITH T‐CELL/HISTIOCYTE‐RICH LARGE B‐CELL LYMPHOMA: A SINGLE INSTITUTION SERIES	5
115 | THE BTK DEGRADER BGB‐16673 AND THE BCL2 INHIBITOR SONROTOCLAX SHOWS ANTI‐TUMOR ACTIVITY AS SINGLE AGENTS AND IN COMBINATION IN MARGINAL ZONE LYMPHOMA MODELS	5
OT04 | GOLSEEK‐1: A PHASE 3, DOUBLE‐BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R‐CHOP VERSUS PLACEBO + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK, LARGE B‐CELL LYMPHOMA	5
453 | EFFICACY AND TOXICITY OF RADIATION THERAPY PRIOR TO CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	5
534 | EFFICACY OF BTK INHIBITOR‐BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA—A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META‐ANALYSIS	5
269 | REAL‐WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH TREATMENT‐NAIVE MANTLE CELL LYMPHOMA IN THE UK, SWEDEN, AND FRANCE	5
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma	5
847 | PALT TRIAL: FIRST IN CLASS GLYCO‐HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA	5
236 | MOSUNETUZUMAB DEMONSTRATES DURABLE CLINICAL BENEFIT IN PATIENTS WITH COMPLETE RESPONSE AND HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	5
771 | TREATMENT OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA COMPLICATED BY SEVERE RENAL FAILURE REQUIRING HEMODIALYSIS	5
Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect	5
179 | GENOMIC AND TRANSCRIPTIONAL SINGLE‐CELL HETEROGENEITY IN GERMINAL‐CENTER LYMPHOMAS: INSIGHTS INTO FOLLICULAR LYMPHOMA TRANSFORMATION	5
634 | OPTIMAL TREATMENT FOR DOUBLE‐EXPRESSOR LYMPHOMA IN THE ERA OF NOVEL AGENTS: A SYSTEMATIC REVIEW AND META‐ANALYSIS	5
The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia	5
588 | SHORT‐COURSE IMMUNOCHEMOTHERAPY FOLLOWED BY SEQUENTIAL ORELABRUTINIB IN PATIENTS WITH HIGH‐RISK MARGINAL ZONE LYMPHOMA	5
555 | ADVERSE EVENTS OF INTEREST WITH ZANUBRUTINIB VERSUS FIXED‐DURATION COMBINATION OF VENETOCLAX + OBINUTUZUMAB IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA	5
219 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL‐321: PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKi PRETREATED CLL/SLL	5
33 | GLOFITAMAB PLUS R‐ICE OR AS MONOTHERAPY IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: UPDATED ANALYSIS FROM THE iMATRIX‐GLO STUDY	5
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMA	5
49 | COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA	5
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs	5
850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA	5
Author Index	5
Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition	5
PROGNOSTIC SIGNIFICANCE OF A NOVEL AMINO ACID METABOLIC INDEX IN CHRONIC LYMPHOCYTIC LEUKEMIA	4
Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin Lymphomas	4
UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) POST‐BRUTON TYROSINE KINASE INHIBITOR (BTKI): A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSIS	4
374 | IMAGING PITFALLS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SEARCH FOR CAYAHL INITIATIVE TO BRIDGE MULTIDISCIPLINARY PATIENT CARE	4
178 | CLINICAL CHARACTERISTICS AND MOLECULAR HETEROGENEITY IN FOLLICULAR LYMPHOMA WITH EXTRANODAL INVOLVEMENT	4
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improv	4
849 | INTERIM PET‐ADAPTED DE‐ESCALATION CHEMOTHERAPY REGIMEN FOR ADVANCED STAGE cHL USING BRENTUXIMAB VEDOTIN, PEMBROLIZUMAB, DOXORUBICIN, AND DACARBAZINE	4
Characterization of the genetic and epigenetic landscape of B‐cell neoplasms with IG::BCL3‐translocation	4
Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report	4
COMBINED MODALITY ULTRA‐LOW‐DOSE ADAPTIVE RADIOTHERAPY AND RITUXIMAB AS TREATMENT STRATEGY FOR INDOLENT NON‐HODGKIN LYMPHOMAS: THE UT SOUTHWESTERN EXPERIENCE	4
Demystifying the diagnostic criteria of indolent systemic mastocytosis	4
LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL‐IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA	4
Deciphering the role of MSI2 as a regulator of stem‐like properties in mantle cell lymphoma	4
MINIMAL DISSEMINATED AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADOLESCENT NON‐HODGKIN LYMPHOMA	4
Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study	4
11 | PREDICTING 2‐YEAR TIME TO PROGRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING ARTIFICIAL INTELLIGENCE ON WHOLE‐BODY PET SCANS	4
385 | THE PROGNOSTIC ROLE OF WHOLE BLOOD EPSTEIN‐BARR VIRUS DNA LOAD IN ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA	4
139 | ENHANCED CAR T‐CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR‐255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA	4
884 | THE EMOTIONAL BURDEN OF LYMPHOMA: HOW LYMPHOMA SURVIVORS PERCEIVE RELATIONSHIPS AND SELF‐IMAGE	4
STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune Response	4
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial	4
COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS	4
Treatment intensification might not improve survival in high‐grade B‐cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled a	4
Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia	4
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data	4
Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas	4
785 | HEMATOLOGIC TOXICITY ANALYSIS OF CAR‐T CELL THERAPY: A RETROSPECTIVE REAL‐WORLD STUDY	4
Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatment	4
Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCL	4
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors	4
326 | GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN 319 REAL WORLD PATIENTS: A RETROSPECTIVE UK ANALYSIS OF EFFICACY, TOLERABILITY AND PRACTICAL IMPLICATIONS	4
Rapid and Sensitive Detection of the MYD88 L265P Mutation for Lymphoplasmocytic Lymphoma/Waldenström's Macroglobulinemia via CRISPR‐Cas12a	4
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia	4
PROTEOMIC PROFILING IDENTIFIES GRANZYME B INHIBITOR SERPIN B9 AS MEDIATOR OF RESISTANCE TO CAR T‐CELL AND BISPECIFIC ANTIBODY TREATMENT IN NODAL B‐CELL LYMPHOMA	4
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis	4
An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment	4
Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma	4
The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis	4
What drives pediatric Burkitt lymphoma? Timing events in the evolution of cancer using single‐cell whole genome sequencing	4
773 | EFFICACY AND SAFETY OF SELINEXOR, CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF MM WITH EXTRAMEDULLARY DISEASE: A PROSPECTIVE MULTI‐CENTER STUDY	3
Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse	3
659 | TREATMENT OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS WITH HIGH CARDIOVASCULAR RISK AND TREATED WITH NON‐ANTHRACYCLINE–CONTAINING REGIMENS	3
637 | THE NON‐STANDARD ROLE OF BISPECIFIC ANTIBODIES IN THE TREATMENT ALGORITHM OF RELAPSED/REFRACTORY DLBCL IN COUNTRIES WITHOUT CART. ARGENTINE EXPERIENCE WITH EPCORITAMAB	3
358 | PD‐1‐BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL‐WORLD ANALYSIS	3
463 | ANTI‐CD19 CAR‐T CELL THERAPY IN RELAPSED/REFRACTORY T‐CELL/HISTIOCYTE‐RICH LARGE B‐CELL LYMPHOMA: INSIGHTS FROM THE FRENCH DESCAR‐T REGISTRY, A LYSA STUDY	3
405 | TRENDS IN THE INCORPORATION OF RADIOTHERAPY IN THE MANAGEMENT OF MULTIPLE MYELOMA OVER THE PAST DECADE: HIGH LOCAL CONTROL RATE AND FACTORS ASSOCIATED WITH ITS DURABILITY	3
222 | EXPLORATION OF SURROGATE MARKERS FOR EZH2 Y646 MUTATION IN FOLLICULAR LYMPHOMA: COMPARATIVE STUDY INCLUDING MATCHED PAIR SAMPLES	3
CIRCULATING TUMOR DNA (LIQUID BIOPSY)	3
Cellular therapy in lymphoma	3
728 | MOLECULAR MECHANISMS INVOLVED IN THE PATHOGENESIS OF POST TREATMENT PERSISTENT ERYTHROCYTOSIS IN PATIENTS WITH HODGKIN LYMPHOMA	3
	3
287 | SHORT‐TERM DOSE‐DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV‐ AND HIV+ PATIENTS WITH BURKITT LYMHOMA	3
412 | IMPROVING THE PREDICTIVE VALUE OF END‐OF‐TREATMENT PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA	3
440 | GOLDILOX: FIRST EXPERIENCE OF TWO DOSING STRATEGIES OF PIRTOBRUTINIB AND GLOFITAMAB FOR MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH COVALENT BTK INHIBITORS	3
64 | NIVOLUMAB + GemOx AS SECOND‐LINE THERAPY FOR PERIPHERAL T CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF A SUB‐COHORT OF THE RANDOMIZED NIVEAU TRIAL	3
Differential ibrutinib sensitivity in Cd79b‐mutant and wildtype subtypes of a novel Myd88‐driven DLBCL mouse model	3
Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation	3
717 | LEPTOMENINGEAL DISEASE IS ASSOCIATED WITH MYC CHROMOSOMAL ALTERATIONS AND WORSE OVERALL SURVIVAL AMONG SECONDARY CNS LYMPHOMA PATIENTS TREATED WITH SALVAGE RADIOTHERAPY	3
709 | STRIKINGLY REDUCED TOXICITIES OF FOTEMUSTINE‐BASED CHEMOTHERAPEUTICS THAN HIGH‐DOSE METHOTREXATE‐CONTAINING REGIMENS WITH COMPARABLE EFFICACY	3
618 | SEQUENTIAL BTK INHIBITOR THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: REAL‐WORLD OUTCOMES AND ATTRITION RATES—FINAL REPORT FROM THE ASIA‐PACIFIC REGISTRY	3
373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP	3
254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY	3
570 | EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA	3
438 | ORELABRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM A GLOBAL PHASE 1/2 STUDY	3
UCLI02 | STATE‐OF‐THE‐ART OF LIQUID BIOPSY IN LYMPHOMA	3